Potential advances in combination chemotherapy for advanced testicular cancer.
An interim analysis of the current EORTC studies in advanced testicular cancer indicates that (a) for low volume metastatic disease the addition of bleomycin (B) to etoposide (E) and cisplatinum (P) may not be necessary, and (b) for high volume metastatic disease the alternating schedule of PVB/BEP is not superior to treatment with BEP. Future studies will subdivide patients into 3 groups. Those with low volume metastatic disease will receive EP using 2 dose schedules for cisplatin. Those with high volume metastases will receive either BEP or etoposide, ifosfamide and cisplatinum (VIP). Those with ultra-high volume metastases will receive BOP/VIP, possibly randomised against another intensive chemotherapy schedule.
Kaye
S B
SB
Gartnavel General Hospital, Glasgow.
Stoter
G
G
Sleijfer
D
D
Jones
W
W
Ten Bokkel Huinink
W
W
Splinter
T
T
Van Oosterom
A
A
Harris
A
A
Boven
E
E
De Pauw
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D009362:Neoplasm Metastasis; D011034:Podophyllotoxin / Q000008:administration & dosage; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D011034:Podophyllotoxin; D002945:Cisplatin; D007069:Ifosfamide